Novacta Therapeutics Achieves 1st Milestone From Wellcome Trust's Strategic Translational Award For A New Treatment For C. Difficile Infection
Medical News Today (Free subscription) | 10/07/2008
... therapy. In addition, exploratory data have demonstrated that the drug is safe and well-tolerated. Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said: 'The increasing incidence of C. difficile infections poses a serious challenge to those entrusted with the care of individuals at risk, both in the hospital and care-home environments. New treatments are needed, as well...
- add comment
- send to a friend
- Explore : Health

















